Goswami Prabuddhagopal, Medhi Gajendra Kumar, Armstrong Gregory, Setia Maninder Singh, Mathew Shajan, Thongamba Gay, Ramakrishnan Lakshmi, George Bitra, Singh Rakesh Kumar, Paranjape Ramesh S, Mahanta Jagadish
FHI 360, New Delhi, India.
Regional Medical Research Centre, Dibrugarh, Assam, India.
Int J Drug Policy. 2014 Sep;25(5):853-64. doi: 10.1016/j.drugpo.2014.04.016. Epub 2014 May 28.
The present study describes an assessment of a large-scale intervention, "Avahan", using an evaluation framework that assesses the program coverage, changes in injection patterns, condom use, and STI and HIV prevalence among People Who Inject Drugs (PWID) in two states of India - Manipur and Nagaland.
Program monitoring data and results from two rounds of a cross sectional biological and behavioural surveys in 2006 (Round 1) and 2009 (Round 2) were used. The sample included 839 and 860 PWIDs from Manipur and 821 and 829 PWIDs from Nagaland in Round 1 and Round 2 respectively for current analysis. Bivariate and multivariate analyses were done to measure the changes in behavioural and biological outcomes between the two rounds and to examine the association between programme exposure and behavioural outcomes.
In Manipur, about 77% of the PWIDs were contacted by the peer educators/outreach workers every month and about 18% of the PWIDs visited the clinic every month by March 2010. In Nagaland, however, the proportion of PWIDs visiting the clinic monthly remained low (11% in March 2010). PWIDs in both states were more likely to report 'consistent safe injection practice in the last six months' in Round 2 compared to Round 1 (Manipur: adjusted odds ratio (aOR): 1.88, 95% confidence intervals (CI): 1.46-2.43; Nagaland: aOR: 2.35, 95% CI: 1.86-2.80) PWIDs were also more likely to report consistent condom use with regular partners in Round 2. The prevalence of Hepatitis B virus (HBV) increased in Round 2 in Manipur (11% vs 6%, p<0.001) and Nagaland (8% vs 6%, p=0.05). The prevalence of Hepatitis C virus (HCV) was high and did not change, either in Manipur (67.3% vs 69.9%, p=0.42) and Nagaland (14.7% vs 15.1%, p=0.82). Similarly, the prevalence of HIV did not change significantly between the two Rounds either in Manipur (27.8% in Round 1 vs 29.2% in Round 2, p=0.59) or in Nagaland (1.2% in Round 1 and 1.6% in Round 2 of the IBBA, p=0.82).
Improvements in safe injection practices and consistent condom use with regular partners suggest effectiveness of prevention efforts. However, increase in HBV prevalence and non-decline in HCV and HIV prevalence in both the states also underscore the need to continue and intensify targeted interventions (such as Hepatitis B vaccination, needle exchange programmes, condom distribution) for long term risk reduction among PWID population.
本研究描述了对一项名为“阿瓦汉”的大规模干预措施的评估,使用了一个评估框架,该框架评估了印度两个邦——曼尼普尔邦和那加兰邦注射吸毒者(PWID)中的项目覆盖情况、注射模式变化、避孕套使用情况以及性传播感染和艾滋病毒流行情况。
使用了项目监测数据以及2006年(第一轮)和2009年(第二轮)两轮横断面生物和行为调查的结果。当前分析中,第一轮和第二轮分别包括来自曼尼普尔邦的839名和860名注射吸毒者以及来自那加兰邦的821名和829名注射吸毒者。进行了双变量和多变量分析,以衡量两轮之间行为和生物结果的变化,并检验项目暴露与行为结果之间的关联。
在曼尼普尔邦,到2010年3月,约77%的注射吸毒者每月与同伴教育者/外展工作者接触,约18%的注射吸毒者每月前往诊所。然而,在那加兰邦,每月前往诊所的注射吸毒者比例仍然较低(2010年3月为11%)。与第一轮相比,两个邦的注射吸毒者在第二轮中更有可能报告“过去六个月内始终采用安全注射做法”(曼尼普尔邦:调整优势比(aOR):1.88,95%置信区间(CI):1.46 - 2.43;那加兰邦:aOR:2.35,95%CI:1.86 - 2.80)。注射吸毒者在第二轮中也更有可能报告与固定性伴始终使用避孕套。曼尼普尔邦(11%对6%,p<0.001)和那加兰邦(8%对6%,p = 0.05)的乙型肝炎病毒(HBV)流行率在第二轮有所上升。丙型肝炎病毒(HCV)流行率较高且未发生变化,在曼尼普尔邦(67.3%对69.9%,p = 0.42)和那加兰邦(14.7%对15.1%,p = 0.82)均如此。同样,艾滋病毒流行率在两轮之间在曼尼普尔邦(第一轮27.8%对第二轮29.2%,p = 0.59)或那加兰邦(IBBA第一轮1.2%和第二轮1.6%,p = 0.82)均未显著变化。
安全注射做法的改善以及与固定性伴始终使用避孕套表明预防措施有效。然而,两个邦乙型肝炎病毒流行率的上升以及丙型肝炎病毒和艾滋病毒流行率未下降也凸显了继续并加强针对性干预措施(如乙型肝炎疫苗接种、针头交换计划、避孕套分发)以长期降低注射吸毒者人群风险的必要性。